Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198436 | 1.00 | CYP2C19 (0.59) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL468727 | 1.00 | CYP2C19 (0.59) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| Bromide SCHEMBL30809291 | 0.98 | CYP2C19 (0.57) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL1373205 | 0.98 | CYP2C19 (0.57) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL6548602 | 0.98 | CYP2C19 (0.57) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL30026293 | 0.98 | CYP2C19 (0.57) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| Boric Acid SCHEMBL9387879 | 0.94 | CYP2C19 (0.53) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| Glycolic Acid SCHEMBL12611268 | 0.94 | CYP2C19 (0.53) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| Toluene SCHEMBL30260177 | 0.90 | SMN1; SMN2 (0.55) | CYP2C19CYP2D6SRCLMNAPOLB | |
| SCHEMBL17142353 | 0.87 | PTGS2 (0.55) | CYP2C19LMNAMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113456634-A | Pyrrolopyrrole compositions as Pyruvate Kinase (PKR) activators | 福马治疗股份有限公司 | 2021-10-01 | — | — | CN | claimed |
| US-20210251969-A1 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | YALE UNIVERSITY | 2021-08-19 | — | — | US | claimed |
| US-11071725-B2 | Activating pyruvate kinase R | FORMA THERAPEUTICS, INC. (US) | 2021-07-27 | — | — | US | claimed |
| EP-3680241-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | Forma Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | claimed |
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4622958-A1 | SYNTHESIS OF PYRROLO[3,4-C]PYRROLES | Novo Nordisk Health Care AG (CH) | 2025-10-01 | — | — | EP | disclosed |
| EP-4617276-A2 | PYRUVATE KINASE R (PKR) ACTIVATING COMPOSITIONS | Novo Nordisk Health Care AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-4031133-B1 | PYRUVATE KINASE R (PKR) ACTIVATING COMPOSITIONS | NOVO NORDISK HEALTHCARE AG (CH) | 2025-08-13 | — | — | EP | disclosed |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250032479-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20100029770-A1 | Methods of treating mental retardation, down's syndrome, fragile X syndrome and autism | SEASIDE THERAPEUTICS, LLC (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2083811-A1 | METHODS OF TREATING MENTAL RETARDATION, DOWN'S SYNDROME, FRAGILE X SYNDROME AND AUTISM | Seaside Therapeutics, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2053406-A2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | caprotec bioanalytics GmbH (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| WO-2008066750-A1 | METHODS OF TREATING MENTAL RETARDATION, DOWN'S SYNDROME, FRAGILE X SYNDROME AND AUTISM | SEASIDE THERAPEUTICS, LLC (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20080119517-A1 | COMPOSITIONS AND METHODS FOR PROTECTING AGAINST MITOCHONDRIA COMPONENT-MEDIATED PATHOLOGY | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1797040-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035303-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032479-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRL1, OPRK1 | CYP2C19 86/4885CYP2D6 69/4885SRC 4772/4885 |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | BCL9, USP9X, BCL9L | CYP2C19 2444/4885CYP2D6 4556/4885SRC 2750/4885 |
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | SLC16A3, SLC16A8, SLC16A1 | CYP2C19 214/4885CYP2D6 64/4885SRC 1867/4885 |
| US-11071725-B2 | Activating pyruvate kinase R | PCK1, PDK1, GCKR | CYP2C19 4626/4885CYP2D6 4332/4885SRC 1410/4885 |
| US-20100029770-A1 | Methods of treating mental retardation, down's syndrome, fragile X syndrome and autism | GABRB1, GABRB3, GABRB2 | CYP2C19 3331/4885CYP2D6 4308/4885SRC 3347/4885 |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CYP2C19 459/4885CYP2D6 456/4885SRC 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.